Mr. Trump fired the inspectors general of at least 15 federal agencies on the evening of Jan. 24, according to The Washington Post. The top watchdogs at the Defense DepartmentState Department, Labor Department and the Department of Veterans Affairs were also among those fired.

HHS and its agencies "help health care providers and the public learn about and respond to public health incidents and threats, including outbreaks of infectious diseases," including bird flu, dengue, measles and other diseases, according to the resolution text.

As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices expected to take effect in 2027.

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

And remember, Medicare provides access to about 8,000 drugs ... but what I will tell you is there is a core of personnel at HHS, regardless of administration, that has done dramatically important ...

The Health and Human Services Department won’t issue health advisories, reports or other materials until further notice, with limited exceptions.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.On Jan. 17, CMS announced it will commence negotiations with pharmaceutical companies to lower prices for Medicare Part D coverage for a wide range of drugs to treat multiple forms of cancer,

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but expensive weight-loss drugs.